ABEOHealthcare · BiotechnologyThe 6 Wall Street analysts covering Abeona Therapeutics, Inc. hold a median 12-month price target of $17 — +213.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Abeona Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (68): The business earns solid, repeatable profits on what it owns.
Accruals (32): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ABEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +213.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Oppenheimer | Maintains | Outperform | $22 → $21 |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 16 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2025 | Oppenheimer | Assumes | Outperform | $19 |
| 16 May 2025 | Stifel | Maintains | Buy | — |
| 30 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Mar 2025 | Oppenheimer | Initiates | Outperform | — |
| 19 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Oct 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | $18 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABEO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Abeona Therapeutics, Inc. returned −19.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 62% of US stocks
Cheaper than 13% of US stocks
Cheaper than 39% of US stocks
Cheaper than 73% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 76% of US stocks
Higher than 13% of US stocks
Higher than 2% of US stocks
Higher than 23% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Abeona Therapeutics, Inc. has a market value of $309.7M and an enterprise value of $182.7M.
Revenue in the twelve months to 30 June 2026: $25.5M. The latest quarter grew 2745.0% year on year.
Net income over the same four quarters: −$62.9M, a −246.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$81.5M, after $5.1M of capital spending.
Trailing P/E: 7.8×; forward P/E: −29.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Abeona Therapeutics, Inc. employs 226 people — $113K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Abeona Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SBS Law announced that investors in Abeona Therapeutics Inc. have the opportunity to join a fraud investigation into the company. The notice encourages affected ABEO shareholders to participate in the inquiry.
Why it matters — ABEO watchers would care because a securities fraud investigation could indicate potential legal and reputational risks for the company.
Abeona Therapeutics announced that members of its management team will participate in upcoming investor conferences scheduled for September 2026. The announcement was made on September 2, 2026, via press release.
Why it matters — ABEO watchers would care because management's participation in investor conferences provides potential opportunities for investors to hear directly from the company's leadership, though the announcement itself conveys no new financial or operational details.
Abeona Therapeutics announced it granted equity awards to new non-executive employees who recently joined the company. The grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — The inducement grants signal recent employee additions and follow Nasdaq's listing rules for equity compensation to new hires, which ABEO watchers may follow as part of company growth activity.
Abeona Therapeutics reported Q2 revenues of $11.4m and treated five Zevaskyn patients, but missed analyst expectations, causing a 14% stock decline. The company faced operational setbacks in Zevaskyn's rollout, including cancellations and manufacturing issues, while management expects improvement with experience and cited partnered programs with Ultragenyx and Taysha as potential catalysts.
Why it matters — ABEO watchers would care because the earnings miss and rollout difficulties highlight near-term execution risks, while partnered programs and expected operational improvements could shape the stock's direction.
Abeona Therapeutics held its second-quarter 2026 earnings call, and Seeking Alpha published a transcript of the proceedings. The item indicates the company reported on its Q2 2026 financial results and provided related discussion during the call.
Why it matters — ABEO watchers would rely on the transcript for the company's latest quarterly financial results and management commentary.
The 6 Wall Street analysts covering Abeona Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $14 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Abeona Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abeona Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Abeona Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (68 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +213.9% from the last close, and Ticker Nerd's factor model ranks Abeona Therapeutics, Inc. 41 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Abeona Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $28 over the next 12 months.
Abeona Therapeutics, Inc. returned -19.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases.
The most recent item we track (Business Wire, 9 Sept 2026): "ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law". SBS Law announced that investors in Abeona Therapeutics Inc. have the opportunity to join a fraud investigation into the company. The notice encourages affected ABEO shareholders to participate in the inquiry.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases. Its current portfolio centers on ZEVASKYN, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, alongside a pipeline of adeno-associated virus-based programs for ophthalmic and other genetic disorders. The company also develops engineered T-cell and viral vector technologies designed to address high-unmet-need conditions in oncology and rare disease settings. Abeona Therapeutics operates from Cleveland, Ohio, with a fully integrated cGMP manufacturing facility that supports commercial production and clinical development activities. The company serves the biotechnology and advanced therapies market, where it plays a specialized role in translating genetic medicine into targeted treatments for patients with limited therapeutic options.
CEO Dr. Vishwas Seshadri M.B.A., Ph.D. · 226 employees · United States · https://www.abeonatherapeutics.com
